Angiotensin II-Mediated Endothelial Dysfunction: Role of Poly(ADP-ribose) Polymerase Activation
Why the study?
Does PARP activation contribute to Angiotensin II-induced endothelial dysfunction?
Population
Cultured endothelial cells, rats infused with sub-pressor doses of Angiotensin II for 7 to 14 days…
Comparison
PARP inhibitors, PARP deficiency, or… vs Wild-type controls or untreated models
Design
Preclinical
Follow-up
7 to 14 days
Authors
Discussion
Loading...
Member takes
Implication
May identify PARP inhibition as a target in hypertension-related endothelial dysfunction; leaves open clinical translation from animal models.
Structured PICO
Does PARP activation contribute to Angiotensin II-induced endothelial dysfunction?
P
Population
Cultured endothelial cells, rats infused with sub-pressor doses of Angiotensin II for 7 to 14 days, PARP-deficient mice infused with Angiotensin II for 7 days, and spontaneously hypertensive rats
I
Intervention
PARP inhibitors (PJ34 or INO-1001), PARP deficiency, or angiotensin-converting enzyme inhibitor (enalapril)
C
Comparator
Wild-type controls or untreated models
O
Outcome
Development of endothelial dysfunction and PARP activationsurrogate
Angiotensin II induces endothelial dysfunction via PARP activation, suggesting PARP inhibition as a potential therapeutic target in hypertension-related vascular disease.
Cite This Study
Szabó et al. (2004) studied this question.